

## Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

LEXINGTON, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that data for CUDC-907 will be presented at the 20<sup>th</sup> Congress of the European Hematology Association (EHA), being held from June 11 - June 14, 2015 in Vienna, Austria as well as at the 13<sup>th</sup> International Congress on Malignant Lymphoma (ICML), being held from June 17 - June 20, 2015 in Lugano, Switzerland.

Curis and its study investigators will present data from the Phase 1 study of CUDC-907, Curis' proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL.

Additional information on the presentations can be found below.

### CUDC-907 Presentations:

#### **20<sup>th</sup> Congress of EHA:**

**Date/Time:** Friday, June 12, 2015, 17:15 - 18:45 CEST

Abstract Number: P325 (Poster)

Presentation Title: *A Phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma.*

Presenter: Jaye Viner, MD

#### **13- ICML:**

**Date/Time:** Thursday, June 18, 2015, 15:35 - 16:55 CEST (Session 6)

Abstract No: 080 (Oral)

Presentation Title: *A first-in-human trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory/ relapsed lymphoma and multiple myeloma.*

Presenter: Anas Younes, MD

### About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecules antagonists of PDL-1 and IRAK4. Curis is also party to a collaboration agreement with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Senior Vice President, Corporate Strategy and Investor Relations

Curis, Inc.

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Media Contact

David Schull

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com

---

<https://investors.curis.com/Curis-to-Present-CUDC-907-Clinical-Data-at-the-20th-Congress-of-the-European-Hematology-Association-and-the-13th-International-Congress-on-Malignant-Lymphoma>